USE OF RECOMBINANT ERYTHROPOIETIN IN SURG ERY - ARE THE COSTS JUSTIFIED

Authors
WOLFF M FANDREY J JELKMANN W HIRNER A
Citation
M. Wolff et al., USE OF RECOMBINANT ERYTHROPOIETIN IN SURG ERY - ARE THE COSTS JUSTIFIED, Langenbecks Archiv fur Chirurgie, 1996, pp. 143-145
Citations number
4
Categorie Soggetti
Surgery
Journal title
Langenbecks Archiv fur Chirurgie → ACNP
ISSN journal
00238236
Year of publication
1996
Supplement
2
Pages
143 - 145
Database
ISI
SICI code
0023-8236(1996):<143:UOREIS>2.0.ZU;2-K
Abstract
The combination of autologous blood donation and rHuEPO therapy is rar ely justified for medical and economic reasons. Adequate alternative i ndications for the use of rHuEPO perioperatively have yet to be studie d. Therefore, in addition to the increasing costs of safe homologous b lood products and the decreasing costs of recombinant proteins, a reev aluation of the cost-effectivity relationship will be mandatory for rH uEPO in surgery.